Physician profile
Patrick Michael Abel
NPI 1689304917
$928.19
in general payments reported to CMS, 2019-2025
11 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $127 · 2023: $282 · 2024: $97.22 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $175.30 | 2023-2025 | Ingrezza |
| Abbvie INC. | $165.82 | 2023-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $157.04 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.71 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $139.97 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $49.64 | 2024-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $23.80 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $21.52 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $17.56 | 2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $15.07 | 2023 | Quviviq |
| Indivior INC. | $13.76 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.